Corline Biomedical
Logotype for Corline Biomedical

Corline Biomedical (CLBIO) investor relations material

Corline Biomedical Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Corline Biomedical
Q3 2026 earnings summary16 Nov, 2026

Executive summary

  • Q3 revenue was SEK 2.356M versus SEK 1.305M YoY; lower-than-expected orders drove a temporary sales slowdown and a net loss of SEK 4.774M.

  • Management sees growth from Kardium and new medical-device customers, targeting SEK ~200M revenue in 2030 from Kardium alone.

Financial highlights

  • Jan–Sep revenue was SEK 11.335M versus SEK 5.547M; net loss improved to SEK 8.711M from SEK 9.687M.

  • Q3 operating loss was SEK 4.052M versus SEK 3.359M; net loss was SEK 4.774M versus SEK 3.359M.

  • Q3 operating costs rose to SEK 6.440M from SEK 4.972M, reflecting higher raw-material and personnel costs, including consultants.

  • Cash and cash equivalents were SEK 29.869M at Sep 30, 2026, versus SEK 5.818M a year earlier; cash includes Kardium’s USD 1M loan.

Outlook and guidance

  • FY2026 revenue guidance is SEK 16M and EBITDA guidance is negative SEK 10M; Q4 sales are expected to return to H1 2026 levels.

  • FY2027 guidance is SEK 30M revenue with positive EBITDA, alongside a marginal cost increase versus 2026.

  • SEK ~200M revenue in 2030 is projected from the Kardium relationship alone, based on expected PFA growth and successful Globe product launch.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Corline Biomedical earnings date

Logotype for Corline Biomedical
Q4 202616 Feb, 2027
Corline Biomedical
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Corline Biomedical earnings date

Logotype for Corline Biomedical
Q4 202616 Feb, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Corline Biomedical AB is a Swedish biotechnology company focused on developing heparin-based medical solutions to improve outcomes in kidney transplantation and cell therapies. The company’s proprietary Corline Heparin Conjugate (CHC) technology is central to its product offerings. Key products include Renaparin, aimed at improving kidney transplantation by reducing complications during surgery, and Cytoparin, designed for cell therapy applications, particularly in the treatment of type 1 diabetes. The company is headquartered in Uppsala, Sweden, and its shares are listed on the Stockholm Stock Exchange.